Interleukin-1 Blockade in Recently Decompensated Heart Failure

Phase 2

Completed

• Conditions: Heart Failure
• Interventions: Drug: Anakinra (weeks 1-2); Drug: Placebo; Drug: Anakinra (weeks 3-12)

• Registration Number: NCT01936909
• Lead Sponsor: Virginia Commonwealth University

Brief Summary

The RED-HART is a randomized double-blinded placebo-controlled study of Anakinra (IL-1 blocker) in patients with recently decompensated heart failure to determine the safety and efficacy in terms of aerobic exercise capacity and ventilatory efficiency measured with a cardiopulmonary exercise test.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2013-09-03
• Study First Submitted QC: 2013-09-03
• Study First Posted: 2013-09-06
• Study Start: 2014-02
• Primary Completion: 2016-09-23
• Study Completion: 2016-09-23
• Results First Submitted: 2017-09-22
• Status Verified: 2017-11
• Results First Submitted QC: 2017-11-30
• Last Update Submitted: 2017-11-30
• Results First Posted: 2017-12-22
• Last Update Posted: 2017-12-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

All 6 criteria need to be met for enrollment of the patient in the study

1. Primary diagnosis for hospitalization is decompensated heart failure established as the finding at admission of all 2 conditions listed below:

   1. dyspnea or respiratory distress or tachypnea at rest or with minimal exertion;

   2. evidence of elevated cardiac filling pressure or pulmonary congestion (at least one of the conditions must be met);

      • pulmonary congestion/edema at physical exam OR chest X-Ray;
      • plasma Brain Natriuretic Peptide (BNP) levels ≥200 pg/ml;
      • invasive measurement of left ventricular end-diastolic pressure >18 mmHg or of pulmonary artery occluding pressure (wedge) >16 mmHg.

2. The patient has a prior documentation of impaired left ventricular systolic function (ejection fraction <50%) at most recent assessment by any imaging modality (within 12 months).

3. The patient is now clinically stable and meets standard criteria for hospital discharge as documented by all the 3 conditions listed below:

   1. absence of dyspnea or pulmonary congestion/distress at rest;
   2. absence of pitting edema in the lower extremities, or in any other region;
   3. stable hemodynamic parameters (blood pressure, heart rate).

4. The patient is of age ≥21 years old, and is willing and able to provide written informed consent.

5. The patient is willing and able to comply with the protocol (i.e. self administration of the treatment, and exercise protocol).

6. The patient has screening plasma C-reactive protein levels >2 mg/L.

Exclusion Criteria Subjects will not be eligible if they meet any of the following 15 exclusion criteria.

1. The primary diagnosis for admission is NOT decompensated heart failure, including diagnosis of acute coronary syndromes, hypertensive urgency/emergency, tachy- or brady-arrhythmias.
2. Concomitant clinically significant comorbidities that would interfere with the execution or interpretation of the study including but not limited to acute coronary syndromes, uncontrolled hypertension or orthostatic hypotension, tachy- or brady-arrhythmias, acute or chronic pulmonary disease or neuromuscular disorders affecting respiration.
3. Recent (previous 3 months) or planned cardiac resynchronization therapy (CRT), coronary artery revascularization procedures, or heart valve surgeries.
4. Previous or planned implantation of left ventricular assist devices or heart-transplant.
5. Chronic use of intravenous inotropes.
6. Recent (<14 days) use of immunosuppressive or anti-inflammatory drugs (not including Non-Steroidal Anti-Inflammatory Drugs [NSAIDs]).
7. Chronic inflammatory disorder (including but not limited to rheumatoid arthritis, systemic lupus erythematosus).
8. Active infection (of any type);
9. Chronic/recurrent infectious disease (including Hepatitis B virus [HBV], Hepatitis C virus [HCV], and HIV/AIDS).
10. Prior (within the past 10 years) or current malignancy.
11. Any comorbidity limiting survival or ability to complete the study.
12. End stage kidney disease requiring renal replacement therapy.
13. Neutropenia (<2,000/mm3) or Thrombocytopenia (<50,000/mm3).
14. Pregnancy.
15. Angina, arrhythmias, or electrocardiograph (ECG) changes that limit maximum exertion during cardiopulmonary exercise testing obtained during the baseline testing.

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Anakinra (short)	Anakinra (weeks 1-2)	Anakinra 100 mg daily for 2 weeks, followed by placebo for 10 weeks
Anakinra (long)	Anakinra (weeks 1-2)	Anakinra 100 mg daily for 12 weeks
Anakinra (long)	Anakinra (weeks 3-12)	Anakinra 100 mg daily for 12 weeks
Placebo	Placebo	Placebo injections daily for 12 weeks

Primary Outcome Measures

Name	Time	Method
Interval Changes in Peak Oxygen Consumption (VO2)	Baseline to 2 weeks	Interval changes in peak oxygen consumption (VO2) after 2 weeks of anakinra treatment.

Secondary Outcome Measures

Name	Time	Method
Quality of Life Improvement	12 weeks	The Duke Activity Status Index questionnaire will be completed at enrollment and 12 weeks. The scale ranges from 0 (unable to perform any tasks) to 58.20 (able to perform all tasks). Higher scores represent increased ability to perform daily activities and may be interpreted as improved quality of life.
Death or Hospital Admission for Heart Failure	24 weeks	We will monitor survival and hospitalization for heart failure throughout the 24 week follow-up

Trial Locations

Locations (1)

Virginia Commonwealth University; 🇺🇸 Richmond, Virginia, United States